Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study

Neurology

Volumn 68, Issue 10, 2007, Pages 751-756

  Solomon, A ^a,b   Kareholt I ^b,c,d   Ngandu, T ^a,b,c   Winblad, B ^b   Nissinen, A ^d   Tuomilehto, J ^c,e,f   Soininen, H ^a   Kivipelto, M ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d STOCKHOLM UNIVERSITY   (Sweden)

^e UNIVERSITY OF HELSINKI   (Finland)

^f SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; CHOLESTEROL;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE SEVERITY; EDUCATION; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HEALTH SURVEY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION STRUCTURE; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; BLOOD; COMPARATIVE STUDY; GENETICS; LONGITUDINAL STUDY;

AGED; APOLIPOPROTEINS E; CHOLESTEROL; COGNITION DISORDERS; DEMENTIA; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; RISK FACTORS;

EID: 33947500485     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000256368.57375.b7     Document Type: Article

References (34)

1. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
2. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000;20:2255-2260.
3. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-155.
4. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late-life. Neurology 2005;64:277-281.
5. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001;57:1447-1452.
6. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003;61:199-205.
7. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late-life associated with a reduced risk of dementia. Neurology 2005;64:1689-1695.
8. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705-714.
9. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254-260.
10. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999;53:517-521.
11. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997;315:1045-1049.
12. Li G, Shofer JB, Kukull WA, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 2005;65:1045-1050.
13. Slooter AJC, Ruitenberg A, van Duijn CM, Breteler MMB. The effect of ApoE on dementia is not through atherosclerosis: the Rotterdam Study [reply from authors]. Neurology 2000;54:2357-2358.
14. Abbott RD, Sharp DS, Burchfield CM, et al. Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. Ann Epidemiol 1997;7:417-424.
15. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 1997;96:37-43.
16. Hershcopf RJ, Elahi D, Andres R, et al. Longitudinal changes in serum cholesterol in man: an epidemiologic search for an etiology. J Chron Dis 1982;35:101-114.
17. Kivipelto M, Helkala EL, Hänninen T, Laakso MP, Hallikainen M, Alhainen K. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001;56:1683-1689.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome, Arch Neurol 1999;56:303-308.
22. Kivipelto M, Helkala E-L, Häninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study Neurology 2001;56:1683-1689.
23. Tsukamoto K, Watanabe T, Matsushima T, et al. Determination by PCR-RFLP of ApoE genotype in a Japanese population. J Lab Clin Med 1993;121:598-602.
24. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994;110:121-161.
25. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation 1992;86:1046-1060.
26. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
27. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P. Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol 2000;29:49-56.
28. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675-687.
29. Lanti M, Menotti A, Nedeljkovic S, Nissinen A, Kafatos A, Kromhout D. Long-term trends in major cardiovascular risk factors in cohorts of aging men in the European cohorts of the Seven Countries Study. Aging Clin Exp Res 2005;17:306-315.
30. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004;24:806-815.
31. Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol 2004;15:667-672.
32. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-757.
33. Karlamangla AS, Singer BH, Reuben DB, Seeman TE. Increases in serum non-high-density lipoprotein cholesterol may be beneficial in some high-functioning older adults: MacArthur studies of successful aging. J Am Geriatr Soc 2004;52:487-494.
34. Shepherd J, Blauw GJ, Murphy MB, PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630.